You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Prevention of Allergic Rhinitis with Topical Immunomodulating Antibodies

    SBC: Chrysalis BioTherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Up to 30% of the US population are now affected by nasal allergy, resulting in a total (direct and indirect) cost of approximately 14.6 billion per year. Seasonal allergic rhinitis (AR), due to exposure to airborne pollen and molds is a major component of this problem in the US and worldwide. The limitations of current pharmaceutical and specific immunotherapy ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Covalent Vaccine for HIV

    SBC: COVALENT BIOSCIENCE INCORPORATED            Topic: NIAID

    DESCRIPTION (provided by applicant): We propose a Phase I STTR study to develop a novel human immunodeficiency virus (HIV) vaccine strategy with the potential of world-wide efficacy. The HIV/AIDS pandemic remains a major global burden. No test vaccine based on traditional scientific principles has induced sufficiently protective immunity to HIV. Induction of neutralizing antibodies (Abs), the corn ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. A NOVEL BIS-INDOLE COMPOUND AGAINST CATHETER COLONIZATION

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Infections associated with medical devices can be serious and even fatal. Catheter colonization and production of a biofilm on the surface of a catheter shortly after implantation are normally the prelude for infections. A number of antimicrobial-treated catheters have been developed to combat these infections, however, many of them have limited clinical effica ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Developing small molecule therapeutics for lupus

    SBC: Biomedical Research Models, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) affects ~ 2 million Americans with devastating impact on multiple organs, especially the skin, joints, kidney, and brain. Therapeutic strategies for lupus are largely palliative orimmunosuppressive with serious toxicities. No new drugs for SLE have been approved in decades. Thus, novel therapeutic approaches to lupus - par ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Feasibility of a New Thermo-brachytherapy Seed for Concurrent Brachytherapy and H

    SBC: Best Medical International, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Adjuvant administration of radiation therapy with hyperthermia in treatment of cancer has been studied extensively in the past three decades (Deger et al., 2004), but simultaneous delivery of these modalities using thesame source has not been documented. Here we propose feasibility study, development and clinical implementation of a new Thermo-brachytherapy see ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Cancer is America's second leading cause of death. Many approved cancer drugs, such as bortezomib (Velcade), are cytotoxic agents that kill normal cells as well as tumor cells. Therapeutic benefit depends on tumor cellsbeing more sensitive than normal cells, thereby allowing clinical responses to be achieved at relatively safe drug doses; however, damage t ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. CG-GRID: Computational Genetics Grid Resource for Interaction Discovery

    SBC: PARABON COMPUTATION, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Susceptibility to common human diseases such as cancer and cardiovascular disease is determined by numerous genetic factors that interact in a nonlinear manner in the context of an individual's age and environmental exposure. This complex genetic architecture has important implications for the use of genome- wide association studies (GWAS) for identifying ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. High-throughput portable software for fragment-based drug design

    SBC: ACPHARIS            Topic: NIGMS

    DESCRIPTION (provided by applicant): Fragment-based drug design (FBDD) is a combinatorial approach in which individual fragments binding to regions of the target site are selected from a fragment library, and then combined to form potential lead compounds.Interest in this approach has significantly increased during the last few years, with many companies using FBDD methods based on X-ray crystallo ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Emergency Operations Plans for Individuals with Disabilities

    SBC: PRAXIS, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): The proposed project is designed to fill an important yet unmet need by developing an online training program that has the potential for reaching all emergency managers, responders and students in the field of emergencypreparedness with a specific focus on individuals with disabilities. Pursuing this objective, the applicant organization, Praxis, Inc., and the ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Noninvasive neonatal glucose monitor

    SBC: FLUOROMETRIX CORPORATION            Topic: NICHD

    DESCRIPTION (provided by applicant): Abnormally low (hypoglycemia) and abnormally high (hypoglycemia) glucose in neonates can lead to devastating consequences. Thus, constant, accurate and safe glucose monitoring is imperative in neonatal care. However, point-of-care (POC) devices for glucose testing currently used for neonates are originally designed for adults. Thus, they do not address issues s ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government